Molecular and Cellular Pathobiology

PCTAIRE1 Phosphorylates p27 and Regulates Mitosis in Cancer Cells

Teruki Yanagi, Maryla Krajewska, Shu-ichi Matsuzawa, and John C. Reed

Abstract

PCTAIRE1 is distant relative of the cyclin-dependent kinase family that has been implicated in spermatogenesis and neuronal development, but it has not been studied in cancer. Here, we report that PCTAIRE1 is expressed in prostate, breast, and cervical cancer cells, where its RNAi-mediated silencing causes growth inhibition with aberrant mitosis due to defects in centrosome dynamics. PCTAIRE1 was not similarly involved in proliferation of nontransformed cells, including diploid human IMR-90 fibroblasts. Through yeast two-hybrid screening, we identified tumor suppressor p27 as a PCTAIRE1 interactor. In vitro kinase assays showed PCTAIRE1 phosphorylates p27 at Ser10. PCTAIRE1 silencing modulated Ser10 phosphorylation on p27 and led to its accumulation in cancer cells but not in nontransformed cells. In a mouse xenograft model of PPC1 prostate cancer, conditional silencing of PCTAIRE1 restored p27 protein expression and suppressed tumor growth. Mechanistic studies in HeLa cells showed that PCTAIRE1 phosphorylates p27 during the S and M phases of the cell cycle. Notably, p27 silencing was sufficient to rescue cells from mitotic arrest caused by PCTAIRE1 silencing. Clinically, PCTAIRE1 was highly expressed in primary breast and prostate tumors compared with adjacent normal epithelial tissues. Together our findings reveal an unexpected role for PCTAIRE1 in regulating p27 stability, mitosis, and tumor growth, suggesting PCTAIRE1 as a candidate cancer therapeutic target. Cancer Res; 74(20); 5795–807. ©2014 AACR.

Introduction

PCTAIRE1 [also known as cyclin-dependent kinase 16 (Cdk16) and PCTK1] is a member of the PCTAIRE family, a group of kinases related to the Cdk family, which includes PCTAIRE-1, 2, and 3 (1). PCTAIRE1 is broadly expressed, with highest levels in the brain and testis (2). Demonstrated functions for PCTAIRE1 include vesicular exocytosis and protein secretion, neuronal migration, neurite outgrowth, and spermatogenesis (3–7). PCTAIRE1 has a central kinase domain that has amino acid sequence similarity to other Cdk family members, and is flanked by unique N-terminal and C-terminal domains. Although PCTAIRE1 contains a motif reminiscent of cyclin-binding sites found in other Cdk family members (1), the mechanisms responsible for its activation are only partly understood (1, 8). Interaction of the PCTAIRE1 N-terminal domain with cyclin Y stimulates its kinase activity (6), whereas PCTAIRE1 binding to the Cdk5 activator does not result in PCTAIRE1 activation (9).

Furthermore, some transformed cells express elevated levels of PCTAIRE1 (10). p27 (also known as Kip1, cyclin-dependent kinase inhibitor 1B) is a tumor suppressor that regulates cell proliferation, cell motility, and apoptosis (11). Consistent with a tumor suppressor role for p27, loss of nuclear p27 is frequently observed in human malignancies and is associated with high-grade tumors and poor prognosis (11, 12). In contrast with conventional tumor suppressors such as p53, loss of p27 expression commonly occurs not through genetic mutations or epigenetic silencing, but rather via increased proteosomal degradation or relocalization (11, 13, 14). Thus, increased rates of degradation and elevated rates of nuclear export are thought to cause the decreased nuclear levels of p27 seen in tumor cells.

We report here investigations of the role of PCTAIRE1 in tumorigenesis, which provide evidence that PCTAIRE1 plays an indispensable role in proliferation of some types of cancer cells. PCTAIRE1-depleted cancer cells show mitotic arrest associated with centrosome dysregulation. PCTAIRE1 also directly binds p27, and phosphorylates it at Ser10, thereby promoting degradation of this tumor suppressor. In tumor xenografts, conditional knockdown of PCTAIRE1 restored p27 protein expression and suppressed tumor growth. In addition, analysis of primary tumors from patients revealed elevated levels of PCTAIRE1 in many prostate and breast cancers. Taken together, these findings reveal an unexpected role for PCTAIRE1 in cancer cell division, thus suggesting that this kinase may provide a novel target for future discovery of oncology therapeutics.
Material and Methods

Cell lines and cell culture

PPC1, Du145, MDA-MB-468, T47D, MCF7, IMR-90, HeLa, and HEK293T cells were purchased from ATCC. 267B1 and 267B1/K-ras were kind gifts from Dr. Dritschilo (Department of Radiation Medicine, Vincent T. Lombardi Cancer Research Center, Georgetown University School of Medicine, Washington D.C.; ref. 15). All cells were used in less than 6 months of continuous passage.

Reagents and antibodies

Predesigned siRNAs directed against human Cdk1 (s464), Cdk5 (s2825), PCTAIRE1 (1472, 1566, 1656), p27 (s2837), and negative scramble control (#1, #2), were purchased from Life Technologies. Kinase inhibitors (SNS-032 and ABT-869) were purchased from Selleckchem. Antibodies against PCTAIRE1 (mouse: G6.1 Santa Cruz Biotechnology, or rabbit: HPA001366 Sigma), procaspase-3 (#9662, Cell Signaling Technology), cleaved caspase-3 (#9661, Cell Signaling Technology), cleaved PARP (mouse, Cell Signaling Technology), p27 (mouse G173-524; BD, or rabbit C-19; Santa Cruz Technology), phospho-p27 Ser10 (sc-12939, Santa Cruz Technology), phospho-p27 Thr187 (37-9700, Invitrogen), phospho-p27 Thr198 (AF3994, R&D), Lamin-B1 (Invitrogen), phospho-Histone H3 (D2C8, Cell Signaling Technology), p107 (ab4448, Abcam), α-tubulin (T5168, Sigma), HA (3F10, Roche), Myc (Roche), β-actin (Sigma), horseradish peroxidase-conjugated secondary antibodies (GE Healthcare), and Alexa Fluor 488/594-conjugated secondary antibodies (Life Technologies) were purchased from the indicated sources.

Plasmids

Point mutations of PCTAIRE1 (K194M) and p27 (S10A, T187A, T198A) were generated by a PCR-based site-directed mutagenesis method. Expression plasmids for various proteins were constructed in the pcDNA3 vector for transfection or the pET vector for generating recombinant proteins.

RNAi

For transient knockdown, cells were transfected with siRNA duplexes by a reverse transfection method using Lipofectamine RNAiMAX.

Extraction of total RNA and qRT-PCR analysis

Total RNAs were isolated from cultured cells and xenograft tumors using the RNeasy Plus Mini Kit (Qiagen). We reverse transcribed RNA using Superscript III (Life Technologies) according to the manufacturer’s instructions. Complementary transcribed RNA using Superscript III (Life Technologies) was transcribed into cDNA. qRT-PCR analysis was performed according to the manufacturer’s protocol (Wako Chemical). To distinguish cytosolic and nuclear proteins, proteins were fractionated using Nuclear Extract Reagents (active motif) according to the manufacturer’s protocol.

Cell viability assays using ATP measurement

Cells were plated at a density of 5,000 to 10,000 cells per well, and cultured for 48 or 72 hours. Cell Titer Glo solution (Promega) was added at 100 μL per well and the plates were kept in the dark for 15 minutes before reading the luminescence with a luminometer (Luminoskan Ascent; Thermo Scientific Corporation).

Cell growth assay

To measure cell growth rates, 0.5 to 1.0 × 10^5 cells with Tet-inducible shRNA were plated onto 60 mm diameter plates. After 1 day, culture media were changed to that with (ON) or without (OFF) doxycycline (100 ng/mL). The numbers of cells were counted 1, 3, 5, and/or 7 days after seeding. In siRNA experiments, the number of cells was counted 2 or 3 days after transfection.

Clonogenic assay

Cells with Tet-inducible shRNA were seeded at 300 to 1,000 cells per well in 35 mm dishes. Cells were cultured with (ON) or without (OFF) doxycycline for 10 to 14 days. After fixation by methanol, cells were incubated with 0.5% crystal violet dye. A colony was defined as consisting of at least 50 cells.

Cell-cycle analysis by FACS

Cells were fixed with cold 70% ethanol and suspended in 100 μL of PBS containing 0.5 μL of phospho-Histone H3 antibody incubated for 1 hour. After washing by PBS, cells were incubated for 30 minutes with Alexa488-conjugated secondary antibodies. Cells were treated with propidium iodide (20 μg/mL) and ribonuclease A (10 μg/mL), and subjected to cell-cycle analysis using FACS Canto (Becton Dickinson). Total 30,000 events were analyzed.

Analysis of apoptosis

Cells were processed using an Annexin V-PI apoptosis assay kit (Life Technologies) and analyzed total 20,000 events by flow cytometry.

Synchronization

HeLa cells were arrested in G0–G1 phase as previously described (16). To arrest in early S phase, double thymidine block method was applied (10). HeLa cells were arrested in M phase as described (17).

Tet-inducible shRNA constructs

PCTAIRE1 shRNA#1 (GCTCTCATCACTCCTCATT). PCTAIRE1 shRNA#2 (GACCTACATTAAAGCTGGAAC), and scramble-control (CAACAAGATGAAGAGCACAA) were cloned into the inducible pLKO-Tet-On vectors as previously described (18).
Yeast two-hybrid screening

Library screening by the yeast two-hybrid method was performed as described (19) using the pGilda plasmid encoding human PCTAIRE1 as bait, and cDNA libraries derived from human Jurkat T-cells, prostate cancer cell lines (PPC1, Du145, and PC-3), and the EGY48 yeast strain.

Immunofluorescence and confocal microscopy

Immunofluorescence staining was performed as described (20). Cell imaging was accomplished with a LSM710 NLO Zeiss Confocal microscope.

Tumor xenograft experiments

All animal experiments were approved by the Institutional Animal Care and Use Committee of the Sanford-Burnham Medical Research Institute (La Jolla, CA). A total of 5.0 × 10⁶ PPC1 cells resuspended in 200 μL RPMI-1640 were injected subcutaneously into the flanks of nu/nu mice. Tumor volume was calculated using the following formula: (long axis × short axis²)/2.

IHC

Dewaxed tissue sections (4.0–5.0 μm) were immunostained as reported previously (21). The information for patient specimens was described in supplementary Materials and Methods.

Quantitative measurement and statistical analysis

Immunoblots band intensities were measured by ImageJ. Mean and SD were calculated statistically from three determinations. Statistical significance of differences between various samples was determined by Student t test. P < 0.05 was considered significant.

For additional details, refer to the Supplementary Materials and Methods.

Results

Knockdown of PCTAIRE1 regulates tumor cell growth and proliferation

To investigate the effect of PCTAIRE1 knockdown in cancer cells, we performed siRNA experiments using three siRNAs that target PCTAIRE1 mRNA. qRT-PCR and immunoblotting confirmed reduction of mRNA and protein levels by all three siRNAs (Supplementary Fig. S1A and S1B). Next, prostate cancer PPC1 cells were treated with siRNAs and cell viability was assessed 72 hours later. Cultures of PCTAIRE1 knockdown PPC1 cells showed reduced relative numbers of viable cells compared with control cell cultures (Supplementary Fig. S1C). Similar results were obtained by direct cell counting methods (Supplementary Fig. S1D). Annexin V staining showed increased cells in death over time in cultures of PCTAIRE1 RNAi-treated cells (Supplementary Fig. S1E).

We also used tetracycline-inducible shRNA vectors to assess the impact of PCTAIRE1 deficiency on tumor cells. In PPC1 cells that were stably infected with lentivirus expressing two different shRNAs, culturing with the tetracycline analog doxycycline resulted in concentration-dependent reductions in PCTAIRE1 mRNA levels (Supplementary Fig. S1F). Doxycycline-inducible reductions in PCTAIRE1 protein were also observed (Fig. 1A). In contrast, PCTAIRE1-targeting shRNAs did not reduce levels of mRNAs encoding Cdk1, Cdk2, Cdk4, Cdk5, Cdk6, PCTAIRE2, or PCTAIRE3 (data not shown). Compared with control cells ( Tet-OFF), growth rates of doxycycline-stimulated PCTAIRE1 knockdown PPC1 cells (Tet-ON) were significantly diminished 5 days after seeding (Fig. 1B). In clonogenic assays, the number of tumor cell colonies was significantly lower upon PCTAIRE1 knockdown compared with control cells (Fig. 1C). Also, cell death was induced by PCTAIRE1 shRNA expression, as demonstrated by accumulation of Annexin V-positive cells (Supplementary Fig. S1G).

To extend these studies into an in vivo context, we used PPC1 cells containing inducible shRNA (#2) in a tumor xenograft model. Immunocompromised (nu/nu) mice were injected subcutaneously with PPC1 cells, and tumors were allowed to grow for 7 days before doxycycline was added to the drinking water for 12 days to induce the shRNA vector, which resulted in reduced PCTAIRE1 protein expression (Supplementary Fig. S1H). Inducing PCTAIRE1 shRNA expression remarkably suppressed tumor growth (Fig. 1D and E). IHC analysis showed increased expression of apoptotic markers (TUNEL assay and cleaved-PARP) in resected PCTAIRE1 knockdown tumors (Supplementary Fig. S1I). Similar results were obtained using other tumor cell lines, such as Du145, MDA-MB-468, and HeLa cells (Supplementary Fig. S2). From these results, we conclude that PCTAIRE1 regulates proliferation and survival of cancer cells. However, as expected by the heterogeneity of human cancer, the impact of PCTAIRE1 knockdown was not uniform, in that less robust effects were observed with T47D and MCF7 (data not shown).

Next, we assessed the PCTAIRE1 knockdown effect on normal cells. In the human diploid fibroblast line IMR-90, PCTAIRE1 knockdown did not affect cell growth (Fig. 2A–C). To further examine the role of PCTAIRE1 in normal versus transformed cells, we applied PCTAIRE1 siRNAs to immortalized prostate epithelial cells 267B1 and their K-ras (V12) transformed isogenic counterpart 267B1/K-ras cells (15). Cell proliferation assays revealed that PCTAIRE1 knockdown markedly diminished the growth rate of 267B1/K-ras cells, whereas the growth of nontransformed 267B1 cells did not appreciably change with PCTAIRE1 knockdown (Fig. 2D–F). These results suggest that proliferation of transformed cells is preferentially dependent on PCTAIRE1.

PCTAIRE1 plays a role in mitosis in cancer cells

To examine the mechanisms of cell growth suppression caused by PCTAIRE1 knockdown, cell-cycle analyses were performed. In cultures of PCTAIRE1 knockdown cells, the proportion of M-phase cells (4N DNA content and phospho-H3 positive) was increased at 24 to 72 hours, then declined as hypoploid (apoptotic) cells appeared in cultures at 48 to 96 hours (Fig. 3A). Similar results were obtained for HeLa cells (Supplementary Fig. S3A).

To identify a cell-cycle arrest point, we examined the effects of PCTAIRE1 knockdown on cell division using time-lapse video microscopy. Although control PPC1 cells (Tet-OFF)
completed mitosis in a timely fashion (Supplementary Fig. S3B, top), doxycycline-treated PPC1 cells (Tet-ON) experienced cell division defects. Most of the affected cells arrested in prometaphase for several hours (7.5 ± 1.6 hours, mean ± SD, n = 10), and then underwent apoptosis (Supplementary Fig. S3B, bottom).

Figure 1. Knockdown of PCTAIRE1 diminishes PPC1 cell growth. A, protein lysates were generated from PPC1 cells stably containing inducible shRNAs (#1, #2) and scramble control cultured for 48 hours with or without 100 ng/mL doxycycline, and analyzed by immunoblotting. B, PPC1 cells (5.0 × 10^4) stably containing shRNAs were cultured for 24 hours, then stimulated with (ON) or without (OFF) doxycycline. The number of cells were counted (mean ± SD; n = 3). **P < 0.01; ***P < 0.001. C, PPC1 cells with inducible shRNAs were seeded at 300 cells per well. After 24 hours, doxycycline was added. Colonies consisting of >50 cells were enumerated on day 10. All data represent mean ± SD (n = 3). ***P < 0.001. D, PPC1 cells (shRNA#2) were subcutaneously injected into nu/nu mice. When tumor volumes reached 150 to 200 mm³, the animals were provided water with (white circles) or without (black circles) 2% doxycycline (Dox; mean ± SD). ***P < 0.001. E, tumors recovered from sacrificed mice at day 19 were weighed (horizontal line, mean). ***P < 0.001.
During the prophase to prometaphase transition, duplicated centrosomes migrate to opposite poles (22). To explore the reason for the prometaphase arrest of PCTAIRE1 knockdown cells, we examined in more detail the apparent failure of PCTAIRE1 knockdown PPC1 cells to form bipolar spindles. Prometaphase cells exhibiting failure to separate duplicated centrosomes were two to four times more frequent, and constituted more than 40% of the cells in cultures of PCTAIRE1 knockdown PPC1 cells (Tet-ON), compared with control PPC1 cells (Tet-OFF), (Fig. 3B and C). Similar phenotypes were observed in siRNA-mediated knockdown of PCTAIRE1 in PPC1 and 267B1/K-ras cells (Fig. 3D and E and Supplementary Fig. S3C and S3D). However, knocking down PCTAIRE1 in 267B1 immortalized prostate epithelial cells did not increase the frequency of cells showing failure to separate duplicated centrosomes (Supplementary Fig. S3E).
and S3F), suggesting that transforming oncoproteins such as K-ras create PCTAIRE1 dependency for centrosome regulation. Altogether, these results suggest that PCTAIRE1 is indispensable for cell division in susceptible cancer cells but not normal cells.

**PCTAIRE1 phosphorylates p27 at Ser 10**

To identify potential targets of PCTAIRE1, we performed yeast two-hybrid screens of cDNA libraries. From a screen of 15 million initial transformants, 17 were identified that interacted specifically with PCTAIRE1. From this pool of 17 candidate
interactors, two were found to encode the tumor suppressor p27. The p27 protein exhibited specific interactions with PCTAIRE1 in two-hybrid assays as evaluated by yeast transformed with plasmids that contained different bait plasmids encoding the various LexA DNA-binding domain (DBD) fusion proteins [PCTAIRE1, calcyclin-binding protein (CacyBP), FADD, or empty] and different prey plasmids encoding various B42 transactivation domain (TAD) fusion proteins (p27, SIAH1, caspase-8). A, β-galactosidase activity of each colony was scored as blue (+) or white (−) after 90 minutes. B, interactions were detected by transactivation of LEU2 reporter genes. Growth on leucine-deficient medium at 30°C was examined 4 days later. C, PPC1 cells were immunostained with anti-PCTAIRE1 (green) and anti-p27 (red) antibodies and DNA-binding fluorochrome DAPI (blue). Scale bar, 20 μm. D, top, PPC1 cells stably containing inducible shRNA-targeting PCTAIRE1 (shRNA#2) were cultured with (ON) or without (OFF) 100 ng/mL doxycycline (Dox). After 48 hours, cells were treated with MG132 (10 μmol/L) for 4 hours. Cells were fractionated to yield cytosolic and nuclear compartments. Bottom, the expression level of phosphorylated p27 (Ser10) was quantified and normalized relative to total p27. Data were expressed relative to phosphorylated p27 (Ser10) in lane 3 (nuclear fraction without PCTAIRE1 knockdown). *, P < 0.05.

It has been reported that p27 is phosphorylated at Ser10, Thr187, and Thr198 (23). To examine whether PCTAIRE1 phosphorylates p27, PPC1 cells were cotransfected with HA-PCTAIRE1 and Myc-p27, followed by immunoprecipitation using anti-Myc antibody, and analysis of specimens by phospho-SDS-PAGE/immunoblotting. p27 phosphorylation at Ser10 seemed to be remarkably elevated in PCTAIRE1-overexpressing cells (Supplementary Fig. S4C). We also assessed immunoprecipitated proteins using phospho-specific antibodies recognizing p27 phosphorylated at Ser10, Thr187, and Thr198. Again, we found that the levels of p27 phosphorylation at Ser10 were increased in PCTAIRE1-overexpressing cells (Supplementary Fig. S4D and data not shown). Conversely, levels of p27 Ser10 phosphorylation were reduced in PPC1 cells with PCTAIRE1 knockdown (Supplementary Fig. S4E and S4F). By subcellular fractionation, shRNA-knockdown (Tet-ON) resulted in lower levels of endogenous p27 (Ser10) phosphorylation in nuclei compared with control cells (Tet-OFF; Fig. 4D).

Finally, we used an in vitro kinase assay to assess PCTAIRE1 phosphorylation of p27, using purified p27 as substrate and immunoprecipitated PCTAIRE1 as enzyme, thereby confirming that PCTAIRE1 can directly phosphorylate p27 at Ser10 (Supplementary Fig. S4G). In contrast, a kinase-dead PCTAIRE1 mutant (K194M), PCTAIRE2, and PCTAIRE3 did not phosphorylate p27 (Supplementary Fig. S4G and S4H).
PCTAIRE1 phosphorylation of p27 was inhibited by the pan-Cdk inhibitor SNS-032 (Supplementary Fig. S4I).

PCTAIRE1 knockdown leads to p27 accumulation

The levels of p27 are regulated by phosphorylation-induced ubiquitination/degradation (Supplementary Fig. S5A), with phosphorylation at Ser10 playing a critical role (14, 23, 24). PCTAIRE1 knockdown upregulated p27 protein levels in PPC1 cells (Fig. 5A and B and Supplementary Fig. S5B), whereas p27 mRNA levels were unaffected (Supplementary Fig. S5C and S5D). Elevated levels of p27 protein were also observed in PCTAIRE1 knockdown tumor xenografts (Fig. 5C). In contrast, knockdown of Cdk1 or Cdk5 showed no effect on p27 protein levels (Supplementary Fig. S5E and S5F). Upregulation of p27 protein levels by PCTAIRE1 knockdown was also seen for other tumor cell lines, including MDA-MB-468, Du145, and 267B1/K-ras cells (Supplementary Fig. S5G–S5I and S5N). Meanwhile, PCTAIRE1 knockdown did not induce p27 upregulation in T47D, MCF7, IMR-90, or 267B1 cells (Supplementary Fig. S5J–S5O) correlating with the lack of PCTAIRE1 dependence for growth of these cell lines.

As a complement to RNAi experiments, we assessed the impact of PCTAIRE1 overexpression on p27 protein levels using 267B1 cells, which intrinsically contain low PCTAIRE1. Experimentally overexpressing PCTAIRE1 in these cells caused p27 Ser10 phosphorylation (Supplementary Fig. S5P), and reduced p27 protein levels in a proteasome-dependent manner (Supplementary Fig. S5Q). In contrast, expressing kinase dead PCTAIRE1 mutant failed to modulate p27.

The effect of PCTAIRE1 on p27 protein stability was further examined by cyclohexamide (CHX) chase experiments. PPC1 cells with shRNA (#2) were cultured with (ON) or without (OFF) doxycycline for 48 hours whereupon the cells were treated with 25 μg/mL CHX and the rate of p27 turnover was monitored (Fig. 5D). Endogenous p27 protein levels were significantly more stable in PCTAIRE1 knockdown PPC1 cells than in control PPC1 cells, demonstrating that PCTAIRE1 downregulates p27 in a posttranslational manner. Furthermore, based on subcellular fractionation analysis, we determined that PCTAIRE1 knockdown seems to promote p27 accumulation in both nucleus and cytoplasm (Fig. 5E).

Next, we examined the cell-cycle dependence of p27 (Ser10) phosphorylation, p27 accumulation, and mitotic arrest in the context of PCTAIRE1 knockdown. For these experiments, we used HeLa cells in which PCTAIRE1 knockdown upregulates p27 protein (Fig. 6A and B). We used a cell synchronization method to assess regulation of p27 levels, using release from double thymidine block (Supplementary Fig. S6A). The levels of p27 protein in Tet-OFF HeLa cells gradually declined following release from cell-cycle arrest, whereas p27 levels in Tet-ON cells were continuously elevated until M phase, when apoptosis occurred as indicated by cleavage of caspase-3 (Fig. 6C).
cell-cycle–dependent cleavage of caspase-3 during M-phase in PCTAIRE1-deficient cells was independently confirmed by other cell-cycle synchronization procedures (Supplementary Fig. S6B). Finally, we examined whether the phosphorylation of p27 (Ser10) by PCTAIRE1 is dependent on phase of the cell cycle. Phos-tag SDS-PAGE/immunoblot analysis revealed that PCTAIRE1 knockdown modulates p27 phosphorylation (Ser10) during S–M phases (Fig. 6D), which is consistent with a previous study (10).

To investigate the pathogenic mechanism of defective mitosis caused by PCTAIRE1 knockdown in susceptible cancer cell lines, we assessed expression of critical proteins required for centrosome separation: Cdk1, Cdk2, cyclin B1, and Eg5 (25, 26). In PCTAIRE1 knockdown cells, protein expression of these molecules was normal (Supplementary Fig. S6C and S6D). Next, we assessed the impact of PCTAIRE1 on interaction of p27 with Cdk5 that it is known to bind and suppress. The p27 protein that accumulated in PCTAIRE1 knockdown cells was found to interact with Cdk1 and Cdk2 (Supplementary Fig. S6E), suggesting that p27 retains its ability to suppress target Cdk5. Cdk1 and Cdk2 are indispensable molecules in centrosome separation because these Cdk5s regulate centrosome localization of Eg5 (27, 28). We determined Eg5 localization during late G2 prometaphase by immunofluorescence microscopy. Although Eg5 colocalized with centrosomes in control cells, Eg5 failed to associate with centrosomes during late G2 prophase in PCTAIRE1 knockdown cells (Supplementary Fig. S6F and S6G).

To confirm the functional role of p27 in the aberrant centrosome dynamics caused by PCTAIRE1 knockdown, PPC1 cells were transfected with siRNAs targeting PCTAIRE1, p27, or both, as well as with various control synthetic RNAs (Fig. 6E). We found that p27 knockdown partially rescued cell viability in cultures of PCTAIRE1 knockdown PPC1 cells (Fig. 6F). Knockdown of p27 also substantially improved growth of PCTAIRE1 knockdown cells (Fig. 6G). Furthermore, the frequency of unseparated duplicated centrosomes was decreased in p27/PCTAIRE1 double knockdown compared with PCTAIRE1-siRNA knockdown cells (Fig. 6H).

Elevated levels of PCTAIRE1 in malignant tissues
We assessed the status of PCTAIRE1 expression in primary prostate and breast tumor specimens by IHC using tissue microarrays (TMA). To characterize the specificity of the anti-PCTAIRE1 antibody, immunoblot analysis was performed (Supplementary Fig. S7A–S7C). PCTAIRE1 immunostaining was very low in normal prostate glands (Fig. 7A–C), but markedly higher in both prostatic intraepithelial neoplasia (PIN) and invasive cancers (Fig. 7A and C). Comparison of PCTAIRE1 immunostaining with Gleason grade revealed low expression levels in very well-differentiated tumors (Gleason grade 2) compared with less differentiated tumors (Gleason grades 3–5; Fig. 7D).

For breast cancer analyses, TMAs containing tumor specimens derived from 121 patients were immunostained. PCTAIRE1 expression was significantly elevated in in situ carcinomas and invasive cancers compared with normal mammary epithelium (Fig. 7E–G). Significantly higher levels of PCTAIRE1 protein in invasive cancers were associated with increasing histologic grade (Fig. 7H), more advanced stage of disease (Fig. 7I), and negative immunostaining for progesterone receptor (PR; Fig. 7J). In this specimen collection, no correlations were found between PCTAIRE1 protein expression and tumor size, estrogen receptor-α status, or survival. On the basis of the IHC pattern of staining, the localization of PCTAIRE1 in primary tumors seemed to inclde both nuclei and cytoplasm (Supplementary Fig. S7D).

We further examined the expression of p27 in the prostate TMA samples, which showed that PCTAIRE1 and p27 levels were inversely correlated (Supplementary Fig. S7E and S7F). These findings are consistent with our cell culture results showing that knockdown of PCTAIRE1 stabilizes p27.

Next, we assessed PCTAIRE1 and p27 protein expression levels in various cell lines. Compared with normal cell lines (IMR-90 and 267B1 cells), tumor cell lines (PC3, DU145, 267B1/K-ras, HeLa, and MDA-MB-468, which are sensitive to PCTAIRE1 knockdown) showed higher PCTAIRE1 and lower p27 protein levels (Supplementary Fig. S7G). In breast cancer MCF7 and T47D cells, which are not sensitive to PCTAIRE1 knockdown, p27 expression levels were higher compared with other cancer cells. These results suggest that baseline expression levels of p27 and PCTAIRE1 may differentiate PCTAIRE1–dependent from –independent malignancies.

We also assessed PCTAIRE1 protein isoforms based on the evidence for diverse PCTAIRE1 isoforms in mouse tissues (6). Compared with PCTAIRE1–knockdown cell lysates (used as negative controls), only one band was detected for human PCTAIRE1 (Supplementary Fig. S7H). suggesting the presence of only one major isoform of PCTAIRE1 in the human cell lines we assessed.

To further assess the role of PCTAIRE1 in cancers, we used the Oncomine data base to evaluate the levels of PCTAIRE1 expression. When 15 studies containing informative PCTAIRE1 expression levels were combined, PCTAIRE1 was identified as one of the most upregulated genes in cancers compared with corresponding normal tissues (Supplementary Fig. S8A). Furthermore, several studies showed evidence of PCTAIRE1 copy number gains in cancers (Supplementary Fig. S8B), which suggests that gene amplification may be one of the reasons for PCTAIRE1 overexpression. Finally, the prognostic value of PCTAIRE1 was assessed using Kaplan–Meier Plotter, an online tool to correlate survival with gene expression, based upon microarray data from 1,405 patients with lung cancer and 1,115 patients with breast cancer. High PCTAIRE1 mRNA levels were significantly correlated with lower overall survival in lung (Supplementary Fig. S8C) and breast cancers (Supplementary Fig. S8D).

Discussion
We report here an unexpected role for PCTAIRE1 in cancer cell division (Fig. 7K). In normal tissues, PCTAIRE1 is highly expressed in testis and brain (2). A physiologic function for PCTAIRE1 was discovered in neurons of PCT–1–mutant nematodes (29), while PCTAIRE1 was implicated by gene ablation studies in mice to be involved in spermatogenesis (6). Analysis...
Figure 6. PCTAIRE1 regulates phosphorylation/degradation of p27 during S–M phases and p27 knockdown rescues PCTAIRE1 knockdown-mediated proliferation arrest. A, forty-eight hours after siRNA transfection, cell lysates were analyzed by immunoblotting. B, HeLa cells with inducible shRNAs were cultured for 48 hours with (ON) or without (OFF) doxycycline. Protein lysates were analyzed by immunoblotting. C, HeLa cells with shRNAs (#2) were cultured for 48 hours with (ON) or without (OFF) doxycycline. Cells were synchronized by a double thymidine block. Cell lysates were subjected to immunoblot analysis. D, HeLa cells with shRNA (#2) were cultured for 2 days with (ON) or without (OFF) doxycycline and synchronized by a double thymidine block. At 4 hours before cell lysate harvesting, MG132 (10 μmol/L) was added to the media. Cell lysates were immunoprecipitated with rabbit anti-p27 antibody and subjected to phos-tag SDS-PAGE, followed by immunoblotting with mouse anti-p27. Phosphorylated p27 (Ser10) was quantified by densitometry and normalized by total p27 expression (mean ± SD; n = 3). E and F, PPC1 cells were transfected with scramble-control RNA or siRNAs targeting PCTAIRE1 and p27 in various combinations as indicated (5 nmol/L each; total siRNA concentration was 10 nmol/L). After 48 hours, cell lysates were analyzed by immunoblotting (E). Cellular ATP levels were measured, with the data expressed as a ratio relative to cells transfected with scramble-control RNA (mean ± SD; n = 3; †, P < 0.05; ‡, P < 0.001). G, forty-eight hours after siRNA transfection, the number of cells was counted (mean ± SD; n = 3). H, the percentage of cells with unseparated duplicated centrosomes among prometaphase cells was enumerated. Columns, mean (n = 3, determinations based on examination of 100 prometaphase cells); bar, SD. **, P < 0.01; †††, P < 0.001.
of PCTAIRE1 knockout mice revealed no essential requirement of PCTAIRE1 for cell proliferation in normal tissues because PCTAIRE1-deficient mice are viable (6). Consistent with these reports, we also did not detect a role for PCTAIRE1 in proliferation of nontransformed cells. Rather, the participation of PCTAIRE1 in cell division was evident in certain cancerous cells.

Our study identified the tumor suppressor p27 as a novel substrate of PCTAIRE1. The importance of p27 as a negative regulator of cell proliferation is illustrated by the phenotype of p27−/− mice, which exhibit increased body size and are predisposed to tumorigenesis (30–33). The main phosphorylation site on p27 is Ser10, which has been found to regulate both its subcellular localization and stability (34, 35). Interestingly, Ser10 phosphorylation can be associated with either stabilization or degradation of p27, depending on the cell cycle. For example, phosphorylation at this site, or mutation of Ser10 to a phospho-mimetic residue (Asp or Glu), correlates with increased stability of p27 in nondividing cells (34–37). In contrast, Ser10 phosphorylation has also been linked to p27 degradation in cycling cells. Several groups reported that p27 Ser10 phosphorylation was required for its export from the

![Figure 7](image_url)
nucleus (34–36, 38–40), which may trigger p27 degradation (24). Phosphorylation of Ser10 has additionally been suggested to be involved in a cancer-related p27 degradation pathway. Phosphorylation-resistant p27-S10A-knock-in mice are partially resistant to urethane-induced tumorigenesis (41). Thus, phosphorylation of Ser10 may constitute an important pathway by which tumor cells modulate the tumor suppressor function of p27.

Several kinases are capable of phosphorylating p27 at Ser10. For example, Mirk/Dyrk1B phosphorylates and stabilizes p27 in quiescent cells (37), whereas hKIS phosphorylates this site at the G0–G1 phase transition following mitogen stimulation, which is accompanied by translocation of p27 (36). Cdk5 also phosphorylates p27 at Ser10 and promotes neural migration in the developing cerebral cortex (42). Other kinases, such as PKB/Akt and ERK2, were reported to phosphorylate p27 at Ser10 (34, 43). These various protein kinases may be capable of modulating the tumor suppressor function of p27, implying considerable redundancy in the mechanisms that promote malignant cell growth via p27 dysregulation. In this regard, although PCTAIRE1 knockdown caused mitotic defects in PPC1, Du145, MDA-MB-468, HeLa, and 267B1/K-ras cells, we observed no remarkable reduction in cell proliferation or survival upon PCTAIRE1 knockdown in the T47D and MCF7 cells. Thus, the role of PCTAIRE1 in p27 dysregulation is likely to be heterogeneous among cancers, and further analysis will be required to differentiate PCTAIRE1-dependent from -independent malignancies.

Our study also suggested a novel role for PCTAIRE1 and p27 in the regulation of centrosome dynamics. Although the role of p27 in the late phase of the cell cycle is unclear, several studies indicated that p27 participates in mitosis. Knockout of Skp2 leads to impaired degradation of p27 (44). In Skp2 knockout mice, several tissues display an increase in cell size, DNA content, and proliferation defects (44–46). These phenotypes are rescued in double Skp2−/−p27−/− mice, suggesting that the accumulation of p27 in Skp2−/− cells is responsible for the failure to progress through mitosis (45, 46). Though the underlying mechanism is unknown by which aberrant p27 expression causes perturbations in centrosome dynamics, we detected a defect in Eg5 localization to centrosomes in dividing cells, consistent with previous studies (27, 28), suggesting that accumulated p27 may affect centrosome dynamics via a Cdk1/Cdk2-Eg5 pathway.

In summary, inhibition of PCTAIRE1 in tumors containing pathologic elevation of this kinase may provide a strategy for improved treatments of some forms of human cancer. In this context, PCTAIRE1 inhibitors would be predicted to restore expression of tumor suppressor p27, reestablishing a mechanism that interferes with prometaphase to metaphase transition (presumably by altering centrosome dynamics) and thereby causing apoptosis to circumvent the propagation of malignant cells. Furthermore, the contribution of p27 to prometaphase-metaphase arrest is presumably only relevant to certain transformed cells possessing defects in cell-cycle check point regulation.

Disclosure of Potential Conflicts of Interest

J.C. Reed is an employee of Roche. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S.-I. Matsuzawa
Development of methodology: T. Yanagi, S.-I. Matsuzawa
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): T. Yanagi, M. Krajewska, S.-I. Matsuzawa
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): T. Yanagi, M. Krajewska, S.-I. Matsuzawa
Writing, review, and/or revision of the manuscript: T. Yanagi, M. Krajewska, S.-I. Matsuzawa, J.C. Reed
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Yanagi, S.-I. Matsuzawa
Study supervision: S.-I. Matsuzawa

Acknowledgments

The authors thank the members of the UCI NCI SPECS consortium of the Strategic Partners for the Evaluation of Cancer Signatures, Prostate Cancer, who contributed to the prostate sample collection, the assignment of Gleason scores, and generation of TMAcs. DVS Dan Mercola, Jessica Wang Rodriguez, Philip Carpenter, and Stan Krajewska, and DRS J. Duffy and Susan Kennedy for breast cancer tissue samples.

Grant Support

T. Yanagi was supported by JSPS fellowships for research abroad, Kanae Foundation, and Sumitomo Life Social Welfare Service Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 25, 2014; revised August 11, 2014; accepted August 21, 2014; published OnlineFirst September 9, 2014.

References


PCTAIRE1 Phosphorylates p27 and Regulates Mitosis in Cancer Cells

Teruki Yanagi, Maryla Krajewska, Shu-ichi Matsuzawa, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-0872

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/09/09/0008-5472.CAN-14-0872.DC1

Cited articles
This article cites 46 articles, 22 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/20/5795.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/74/20/5795.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.